CRON on Nasdaq
Cronos Group Inc
Logo: thecronosgroup.com4
Canadian health care company based in Toronto, founded in 20121
In its 2026 annual report the company says: “Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development.”7 Its chief executive is Michael Gorenstein.1
Price unavailable
Last updated Oct 21, 2026.
Overview
2012Founded1
Compare with Natural Alternatives International, MARIMED INC. or Niagen Bioscience, Inc., or pick any stock.
- TickerCRON on Nasdaq1
- Industryhealth care1
- HeadquartersToronto, Canada1
- Websitethecronosgroup.com
- Incorporated inBritish Columbia, Canada5
- Business address4491 Concession Rd 12, Stayner, A6 L0M 1S05
- Filer categoryAccelerated filer5
- Legal formBusiness corporations (which includes professional corporations)3
- LEI549300CWB04E8UOTWX713
- StatusActive3
- LEI statusLapsed (not renewed)3
- Registered address111 Peter Street, Unit 300, M5V 2H1 Toronto, Canada3
- Registered withMinistry of Government and Consumer Services, 0023394983
See how the biggest companies compare on our leaderboards
Cronos is incorporated under the laws of the Province of British Columbia with principal executive offices located at 4491 Concession Rd 12, Stayner, Ontario L0M 1S0. The Company’s telephone number is +1-416-504-0004, the website is https://thecronosgroup.com/ and the investor relations section of the website is https://ir.thecronosgroup.com/. All references to Cronos’ website are inactive references, are for informational purposes only and are not intended to incorporate any information from or referenced on its website into this Annual Report.7 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
42.8%Gross margin8
-11.9%Operating margin8
-6.4%Net margin8
24.6%Revenue growth, 20258
-0.9%Return on equity8
$149.0KFree cash flow8
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Cannabis Flower brought in 74% of the revenue Cronos Group Inc broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Cannabis Flower | $62.1M | $87.9M | $108.5M |
| Cannabis Extracts | $24.6M | $29.2M | $37.7M |
| Product and Service, Other | $602.0K | $535.0K | $411.0K |
Regions
Canada brought in 62% of the revenue Cronos Group Inc broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| Canada | $64.7M | $82.4M | $90.3M |
| Israel | $21.1M | $28.4M | $41.8M |
| Other Countries | $1.4M | $6.8M | $14.5M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development3¢$4.4M
- Other costs87¢$127.9M
- Income tax10¢$14.2M
Out of $146.6M in revenue.8 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending73¢$25.7M
- Share buybacks27¢$9.7M
Out of $25.9M of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.8
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net revenue, before excise taxes | $193.4M | $161.8M | $120.3M |
| Excise taxes | -$46.8M | -$44.2M | -$33.0M |
| Net revenue | $146.6M | $117.6M | $87.2M |
| Cost of sales | $83.2M | $91.7M | $74.5M |
| Inventory write-down | $654.0K | $707.0K | $805.0K |
| Gross profit | $62.8M | $25.2M | $11.9M |
| Sales and marketing | $21.8M | $21.6M | $22.7M |
| Research and development | $4.4M | $4.2M | $5.8M |
| General and administrative | $42.0M | $46.5M | $49.5M |
| Restructuring costs | $2.0M | $630.0K | $1.5M |
| Share-based compensation | $7.0M | $8.7M | $8.8M |
| Depreciation and amortization | $2.1M | $3.7M | $5.0M |
| Impairment loss on goodwill and indefinite-lived intangible assets | $700.0K | $0 | $0 |
| Impairment loss on long-lived assets | $36.0K | $16.4M | $3.4M |
| Total operating expenses | $80.2M | $101.7M | $96.7M |
| Operating loss | -$17.4M | -$76.5M | -$84.8M |
| Interest income, net | $40.0M | $52.0M | $51.2M |
| Share of income from equity method investments | $0 | $2.4M | $1.6M |
| Gain on revaluation of loan receivable | $0 | $11.8M | $0 |
| Gain on revaluation of equity method investment | $0 | $32.5M | $0 |
| Loss on revaluation of financial instruments | -$452.0K | -$6.2M | -$12.0M |
| Impairment loss on other investments | $0 | -$25.6M | -$23.4M |
| Foreign currency transaction gain (loss) | -$28.6M | $57.9M | -$7.3M |
| Loss on held-for-sale assets | -$5.5M | -$11.2M | $0 |
| Change in allowance for credit loss on non-operating loan | -$4.9M | $0 | $0 |
| Other, net | -$241.0K | -$301.0K | $1.0M |
| Total other income | $275.0K | $113.1M | $11.1M |
| Income (loss) before income taxes | -$17.1M | $36.6M | -$73.7M |
| Income tax benefit | -$14.2M | -$3.4M | -$3.2M |
| Income (loss) from continuing operations | -$2.9M | $40.0M | -$70.4M |
| Loss from discontinued operations | $0 | $0 | -$4.1M |
| Net income (loss) | -$2.9M | $40.0M | -$74.6M |
| Net income (loss) attributable to non-controlling interest | $6.5M | -$1.1M | -$590.0K |
| Net income (loss) attributable to Cronos Group | -$9.4M | $41.1M | -$74.0M |
| Foreign exchange gain (loss) on translation | $48.7M | -$86.3M | $21.5M |
| Comprehensive income (loss) | $45.8M | -$46.3M | -$53.0M |
| Comprehensive income (loss) attributable to non-controlling interest | $8.6M | -$3.2M | -$526.0K |
| Comprehensive income (loss) attributable to Cronos Group | $37.2M | -$43.1M | -$52.5M |
| Basic - continuing operations (in dollars per share) | -$0 | $0 | -$0 |
| Basic - discontinued operations (in dollars per share) | $0 | $0 | -$0 |
| Basic net income (loss) per share attributable to Cronos Group (in dollars per share) | -$0.02 | $0.11 | -$0.19 |
| Diluted - continuing operations (in dollars per share) | -$0 | $0 | -$0 |
| Diluted - discontinued operations (in dollars per share) | $0 | $0 | -$0 |
| Diluted net income (loss) per share attributable to Cronos Group (in dollars per share) | -$0.02 | $0.11 | -$0.19 |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $791.8M | $858.8M | ||
| Short-term investments | $40.0M | $0 | ||
| Accounts receivable, net | $34.1M | $15.5M | ||
| Interest receivable | $8.7M | $8.7M | ||
| Other receivables | $14.4M | $5.0M | ||
| Current portion of loans receivable, net | $0 | $618.0K | ||
| Inventory, net | $46.8M | $33.1M | ||
| Prepaids and other current assets | $8.3M | $6.3M | ||
| Held-for-sale assets | $0 | $8.1M | ||
| Total current assets | $944.1M | $936.1M | ||
| Other investments | $7.7M | $2.8M | ||
| Non-current portion of loans receivable, net | $20.8M | $15.5M | ||
| Property, plant and equipment, net | $145.9M | $133.2M | ||
| Right-of-use assets | $1.4M | $1.4M | ||
| Goodwill | $66.5M | $63.5M | ||
| Intangible assets, net | $8.9M | $11.3M | ||
| Deferred tax assets | $1.9M | $2.6M | ||
| Total assets | $1.2B | $1.2B | ||
| Accounts payable | $11.6M | $17.0M | ||
| Income taxes payable | $0 | $9.0K | ||
| Accrued liabilities | $36.2M | $31.7M | ||
| Current portion of lease obligation | $337.0K | $1.0M | ||
| Derivative liabilities | $0 | $40.0K | ||
| Total current liabilities | $48.2M | $49.7M | ||
| Non-current portion due to non-controlling interests | $733.0K | $1.1M | ||
| Non-current portion of lease obligation | $1.2M | $993.0K | ||
| Deferred tax liabilities | $4.1M | $3.6M | ||
| Total liabilities | $54.2M | $55.3M | ||
| Share capital and additional paid-in capital (no par value; authorized for issue as of December 31, 2025 and 2024: unlimited; shares outstanding as of December 31, 2025 and 2024: 381,592,969 and 382,530,780, respectively) | $663.0M | $669.9M | ||
| Retained earnings | $447.8M | $457.7M | ||
| Accumulated other comprehensive loss | -$16.8M | -$63.5M | ||
| Total equity attributable to shareholders of Cronos Group | $1.1B | $1.1B | ||
| Non-controlling interests | $49.1M | $46.9M | ||
| Total shareholders equity | $1.1B | $1.1B | $1.1B | $1.1B |
| Total liabilities and shareholders equity | $1.2B | $1.2B | ||
| Common stock, shares issued (in shares) | 381.6M shares | 382.5M shares | ||
| Common stock, shares outstanding (in shares) | 381.6M shares | 382.5M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $791.8M | $858.8M | ||
| Short-term investments | $40.0M | $0 | ||
| Accounts receivable, net | $34.1M | $15.5M | ||
| Interest receivable | $8.7M | $8.7M | ||
| Other receivables | $14.4M | $5.0M | ||
| Current portion of loans receivable, net | $0 | $618.0K | ||
| Inventory, net | $46.8M | $33.1M | ||
| Prepaids and other current assets | $8.3M | $6.3M | ||
| Held-for-sale assets | $0 | $8.1M | ||
| Total current assets | $944.1M | $936.1M | ||
| Other investments | $7.7M | $2.8M | ||
| Non-current portion of loans receivable, net | $20.8M | $15.5M | ||
| Property, plant and equipment, net | $145.9M | $133.2M | ||
| Right-of-use assets | $1.4M | $1.4M | ||
| Goodwill | $66.5M | $63.5M | ||
| Intangible assets, net | $8.9M | $11.3M | ||
| Deferred tax assets | $1.9M | $2.6M | ||
| Total assets | $1.2B | $1.2B | ||
| Accounts payable | $11.6M | $17.0M | ||
| Income taxes payable | $0 | $9.0K | ||
| Accrued liabilities | $36.2M | $31.7M | ||
| Current portion of lease obligation | $337.0K | $1.0M | ||
| Derivative liabilities | $0 | $40.0K | ||
| Total current liabilities | $48.2M | $49.7M | ||
| Non-current portion due to non-controlling interests | $733.0K | $1.1M | ||
| Non-current portion of lease obligation | $1.2M | $993.0K | ||
| Deferred tax liabilities | $4.1M | $3.6M | ||
| Total liabilities | $54.2M | $55.3M | ||
| Share capital and additional paid-in capital (no par value; authorized for issue as of December 31, 2025 and 2024: unlimited; shares outstanding as of December 31, 2025 and 2024: 381,592,969 and 382,530,780, respectively) | $663.0M | $669.9M | ||
| Retained earnings | $447.8M | $457.7M | ||
| Accumulated other comprehensive loss | -$16.8M | -$63.5M | ||
| Total equity attributable to shareholders of Cronos Group | $1.1B | $1.1B | ||
| Non-controlling interests | $49.1M | $46.9M | ||
| Total shareholders equity | $1.1B | $1.1B | $1.1B | $1.1B |
| Total liabilities and shareholders equity | $1.2B | $1.2B | ||
| Common stock, shares issued (in shares) | 381.6M shares | 382.5M shares | ||
| Common stock, shares outstanding (in shares) | 381.6M shares | 382.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income (loss) | -$2.9M | $40.0M | -$74.6M |
| Share-based compensation | $7.0M | $8.7M | $8.8M |
| Depreciation and amortization | $14.2M | $9.3M | $8.1M |
| Impairment loss on goodwill and indefinite-lived intangible assets | $700.0K | $0 | $0 |
| Impairment loss on long-lived assets | $36.0K | $16.4M | $3.6M |
| Impairment loss on other investments | $0 | $25.6M | $23.4M |
| Loss from investments | $446.0K | $3.8M | $10.5M |
| Changes in expected credit losses on long-term financial assets | $4.9M | $1.0M | -$1.5M |
| Revaluation of equity method investment | $0 | -$32.5M | $0 |
| Revaluation of loan receivable | $0 | -$11.8M | $0 |
| Loss on held-for-sale assets | $5.5M | $11.2M | $0 |
| Inventory step-up recorded to cost of sales | $517.0K | $5.3M | $0 |
| Foreign currency (gain) loss | $28.6M | -$57.9M | $7.3M |
| Other non-cash operating activities, net | $1.2M | -$131.0K | -$1.9M |
| Accounts receivable, net | -$16.7M | -$917.0K | $9.2M |
| Interest receivable | -$11.0K | -$3.7M | -$14.3M |
| Other receivables | -$9.0M | $2.1M | -$1.4M |
| Prepaids and other current assets | -$1.8M | -$512.0K | $1.4M |
| Inventory, net | -$10.4M | $7.4M | $7.4M |
| Accounts payable | $1.1M | -$7.4M | -$773.0K |
| Income taxes payable | -$10.0K | -$93.0K | -$33.1M |
| Accrued liabilities | $2.4M | $2.8M | $5.2M |
| Net cash provided by (used in) operating activities | $25.9M | $18.8M | -$42.8M |
| Purchase of short-term investments | -$40.0M | $0 | -$608.2M |
| Proceeds from short-term investments | $0 | $185.8M | $532.8M |
| Purchase of other investments | -$5.1M | $0 | $0 |
| Proceeds from sale of held for sale assets | $2.8M | $0 | $0 |
| Cash acquired in business combination | $0 | $6.0M | $0 |
| Advances on loans receivable | -$13.3M | -$8.8M | $0 |
| Proceeds from repayment on loans receivable | $5.1M | $5.3M | $16.8M |
| Dividends received from equity method investment | $0 | $0 | $1.3M |
| Dividend proceeds | $0 | $0 | $345.0K |
| Purchase of property, plant and equipment | -$25.7M | -$12.4M | -$2.5M |
| Purchase of intangible assets, net of disposals | -$339.0K | -$743.0K | -$918.0K |
| Other investing activities | $0 | $0 | $860.0K |
| Net cash provided by (used in) investing activities | -$76.6M | $175.1M | -$59.5M |
| Repurchases of common stock | -$9.7M | $0 | $0 |
| Dividend paid to non-controlling interest | -$6.4M | $0 | $0 |
| Withholding taxes paid on share-based awards | -$3.8M | -$1.2M | -$1.0M |
| Net cash used in financing activities | -$19.9M | -$1.2M | -$1.0M |
| Effect of foreign currency translation on cash and cash equivalents | $3.6M | -$3.2M | $8.0M |
| Net change in cash and cash equivalents | -$67.0M | $189.5M | -$95.4M |
| Interest paid | $0 | $0 | $0 |
| Interest received | $39.1M | $48.4M | $36.5M |
| Income taxes paid | $104.0K | $647.0K | $33.0M |
No quarter-by-quarter statement was filed.
Corporate structure
Cronos Group Inc sits at the top of its group. 12 entities, 4 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Cronos Group Inc
- Altria Filed SC 13D/A on Cronos Group Inc, latest Apr 25, 2024 (2 filings since Dec 19, 2022)
- Cronos Group Inc Toronto, Ontario, Canada
- CGM B.V. Subsidiary · Netherlands
- Cronos Growing Company Inc. Subsidiary · Canada
- Cronos Israel G.S. Cultivation Ltd. Subsidiary · Israel
- Cronos Israel G.S. Manufacturing Ltd. Subsidiary · Israel
- Cronos Israel G.S. Pharmacy Ltd. Subsidiary · Israel
- Cronos Israel G.S. Store Ltd. Subsidiary · Israel
- Cronos Research Labs Ltd. Subsidiary · Israel
- Cronos USA Client Services LLC Subsidiary · Delaware, United States
- Cronos USA Holdings Inc. Subsidiary · Delaware, United States
- Hortican Inc. Subsidiary · Canada
- Peace Naturals Project Inc. Subsidiary · Canada
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Cronos Group Inc reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Accumulated depreciation | $42.6M8 Dec 31, 2025 | $29.8M8 Dec 31, 2024 | +43.1% |
| Property and equipment, net | $145.9M8 Dec 31, 2025 | $133.2M8 Dec 31, 2024 | +9.5% |
| Operating-lease assets (leased space) | $1.4M8 Dec 31, 2025 | $1.4M8 Dec 31, 2024 | +2.3% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $791.8M8 Dec 31, 2025 | $858.8M8 Dec 31, 2024 | −7.8% |
| Marketable securities, current | $40.0M8 Dec 31, 2025 | $08 Dec 31, 2024 | |
| Stakes in other companies (equity method) | $012 Dec 31, 2024 | $19.5M12 Dec 31, 2023 | −100.0% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $66.5M8 Dec 31, 2025 | $63.5M8 Dec 31, 2024 | +4.8% |
| Intangible assets, net (excluding goodwill) | $8.9M8 Dec 31, 2025 | $11.3M8 Dec 31, 2024 | −21.0% |
| Finite-lived intangibles, gross | $22.0M8 Dec 31, 2025 | $48.9M8 Dec 31, 2024 | −54.9% |
| Accumulated amortization | $7.4M8 Dec 31, 2025 | $12.1M8 Dec 31, 2024 | −38.8% |
| Finite-lived intangibles, net | $8.1M8 Dec 31, 2025 | $9.8M8 Dec 31, 2024 | −17.1% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $46.8M8 Dec 31, 2025 | $33.1M8 Dec 31, 2024 | +41.0% |
| Raw materials | $8.8M8 Dec 31, 2025 | $5.4M8 Dec 31, 2024 | +62.3% |
| Work in process | $25.8M8 Dec 31, 2025 | $14.3M8 Dec 31, 2024 | +80.0% |
| Finished goods | $12.0M8 Dec 31, 2025 | $13.2M8 Dec 31, 2024 | −9.3% |
| Supplies | $146.0K8 Dec 31, 2025 | $151.0K8 Dec 31, 2024 | −3.3% |
Properties, in its own words
As of December 31, 2025, the Company owned various manufacturing facilities in Canada and Gan Shmuel, Israel. The Company ceased operations at the Cronos Fermentation Facility in Manitoba and sold the property on November 15, 2025. See Part I, Item 1 “Business – Operations and Investments” for further information. Management believes that our existing facilities and the anticipated changes described herein are adequate to meet our current requirements and, to the extent that our facilities are leased, comparable space is readily available.
Item 2 of the 10-K filed Feb 26, 2026.7
Leadership
Who has led Cronos Group Inc, and when. Pick a name to see everywhere that person has worked.
Chief financial officer
201520202025
- Chief executive officerMichael Gorenstein1
- ChairMichael Gorenstein Sep 16, 2020 to Mar 18, 202216
- Chief financial officerJames Holm Nov 14, 2022 to now17
- Chief financial officerRobert L. Madore Aug 11, 2021 to Aug 11, 202218
- Chief financial officerJerry Filomena Barbato Dec 31, 2019 to Dec 31, 201919
Board members and other officers (30)
- OfficerJared Matthew Kenost Feb 26, 2026 to now20
- VP, ControllerLloyd Anderson Wilson Aug 11, 2025 to now21
- SVP, Head of Cronos IsraelAdam Wagner Apr 10, 2024 to now22
- VP, ControllerJames Andrew McGinness Iii. Jun 1, 2023 to now23
- OfficerJohn Griese Jan 12, 2022 to Mar 17, 202224
- General Manager (Israel)Ran Gorelik Apr 28, 2022 to Mar 19, 202425
- OfficerTerrence Gregory Joseph Doucet Apr 28, 2022 to now26
- OfficerArye Weigensberg Aug 18, 2022 to now27
- VP, ControllerCarlos S. Cortez Jun 23, 2021 to Mar 21, 202328
- SVP, Corporate AffairsAnna Shlimak Mar 2, 2020 to now29
- General Manager, USASummer Frein Aug 4, 2020 to Mar 4, 202230
- OfficerKurt Schmidt Sep 10, 2020 to Mar 4, 202231
- SVP, Global Head of PeopleShannon Buggy Nov 10, 2020 to now32
- OfficerJeffrey David Jacobson Dec 31, 2019 to now33
- OfficerMichael Gorenstein Dec 31, 2019 to now34
- Vice President & ControllerPuneet Mathur Dec 31, 2019 to May 13, 202135
- OfficerRobert Steven Rosenheck Dec 31, 2019 to Dec 31, 201936
- OfficerXiu Ming Shum Dec 31, 2019 to Nov 15, 202137
- Board memberDarren Chester Broughton Jun 30, 2026 to now38
- Board memberDominik Meier Jun 30, 2023 to Jun 30, 202339
- Board memberElizabeth Seegar Jun 30, 2023 to Jun 30, 202340
- Board memberKendrick Foster Ashton Jr. Jul 6, 2021 to Aug 10, 202341
- Board memberHeather A. Newman Mar 27, 2020 to Mar 27, 202042
- Board memberBronwen Christine Evans Dec 31, 2019 to Aug 11, 202043
- Board memberBruce Allen Gates Dec 31, 2019 to Dec 31, 201944
- Board memberJames Daniel Rudyk Dec 31, 2019 to now45
- Board memberJason Marc Adler Dec 31, 2019 to now46
- Board memberJody L. Begley Dec 31, 2019 to Dec 31, 201947
- Board memberMichael Gorenstein Dec 31, 2019 to now34
- Board memberMurray R. Garnick Dec 31, 2019 to now48
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- CGM B.V. Netherlands6
- Cronos Growing Company Inc. Canada6
- Cronos Israel G.S. Cultivation Ltd. Israel6
- Cronos Israel G.S. Manufacturing Ltd. Israel6
- Cronos Israel G.S. Pharmacy Ltd. Israel6
- Cronos Israel G.S. Store Ltd. Israel6
- Cronos Research Labs Ltd. Israel6
- Cronos USA Client Services LLC Delaware, USA6
- Cronos USA Holdings Inc. Delaware, USA6
- Hortican Inc. Canada6
- Peace Naturals Project Inc. Canada6
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- PharmaCan Capital Corp.Oct 23, 2015 to May 27, 20165
Timeline
- Oct 15, 20268-K Entered a material agreement; Completed an acquisition or sale; Regulation FD disclosure49
- Sep 11, 20268-K Entered a material agreement50
- Aug 7, 20268-K Shareholder vote51
- Aug 6, 20268-K Results of operations52
- Jun 22, 20268-K Shareholder vote53
- May 11, 20268-K Entered a material agreement; Results of operations; Other events54
- Feb 26, 20268-K Results of operations55
- Dec 9, 20258-K Entered a material agreement; Regulation FD disclosure56
- Nov 6, 20258-K Results of operations57
- Aug 29, 20258-K Executive or director change58
- Aug 7, 20258-K Results of operations; Executive or director change59
- Jun 24, 20258-K Shareholder vote60
- 2012Founded Founded1
Calendar
Coming up
- Nov 5, 2026 · Before the openReports results for the quarter ending Sep/2026 A year earlier it reported $0.07 a share, on Nov 6, 2025.61
When it reported results
- Aug 6, 2026Reported quarterly or annual results52
- May 11, 2026Reported quarterly or annual results54
- Feb 26, 2026Reported quarterly or annual results55
- Nov 6, 2025Reported quarterly or annual results57
- Aug 7, 2025Reported quarterly or annual results59
- May 8, 2025Reported quarterly or annual results62
- Feb 27, 2025Reported quarterly or annual results63
- Nov 12, 2024Reported quarterly or annual results64
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
296 filings to the SEC since October 2021: 5 annual reports, 16 quarterly reports, 51 major events, 204 insider forms, 2 large holders, 18 other. The latest 20:
- Oct 15, 20268-K EDGAR
- Sep 11, 20268-K EDGAR
- Aug 7, 20264 EDGAR
- Aug 7, 20264 EDGAR
- Aug 7, 20264 EDGAR
- Aug 7, 20268-K/A EDGAR
- Aug 6, 202610-Q EDGAR
- Aug 6, 20268-K EDGAR
- Jun 30, 20263 EDGAR
- Jun 22, 20268-K EDGAR
- May 29, 2026SD EDGAR
- May 14, 20264 EDGAR
- May 14, 20264 EDGAR
- May 14, 20264 EDGAR
- May 14, 20264 EDGAR
- May 12, 20264 EDGAR
- May 12, 20264 EDGAR
- May 12, 20264 EDGAR
- May 11, 202610-Q EDGAR
- May 11, 20268-K EDGAR
The 296 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
25 open-market trades by officers, directors and large owners since October 2021: 25 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 30, 2023 | ADLER JASON MARCDirector | Buy | 37,500 | $1.74 | $65.2K | Form 4 |
| May 25, 2023 | ADLER JASON MARCDirector | Buy | 100,000 | $1.80 | $180.0K | Form 4 |
| May 23, 2023 | ADLER JASON MARCDirector | Buy | 100,000 | $1.90 | $190.0K | Form 4 |
| May 19, 2023 | ADLER JASON MARCDirector | Buy | 100,000 | $1.89 | $189.0K | Form 4 |
| May 18, 2023 | ADLER JASON MARCDirector | Buy | 11,420 | $1.80 | $20.6K | Form 4 |
| May 17, 2023 | ADLER JASON MARCDirector | Buy | 59,300 | $1.71 | $101.4K | Form 4 |
| May 16, 2023 | ADLER JASON MARCDirector | Buy | 76,100 | $1.72 | $130.9K | Form 4 |
| May 15, 2023 | ADLER JASON MARCDirector | Buy | 19,000 | $1.76 | $33.4K | Form 4 |
| Dec 15, 2022 | ADLER JASON MARCDirector | Buy | 109,588 | $2.81 | $307.9K | Form 4 |
| Dec 14, 2022 | ADLER JASON MARCDirector | Buy | 94,600 | $2.83 | $267.7K | Form 4 |
| Dec 13, 2022 | ADLER JASON MARCDirector | Buy | 88,152 | $2.89 | $254.8K | Form 4 |
| Dec 12, 2022 | ADLER JASON MARCDirector | Buy | 86,000 | $2.90 | $249.4K | Form 4 |
| Dec 9, 2022 | ADLER JASON MARCDirector | Buy | 129,000 | $2.89 | $372.8K | Form 4 |
| Dec 8, 2022 | ADLER JASON MARCDirector | Buy | 162,400 | $2.86 | $464.5K | Form 4 |
| Dec 7, 2022 | ADLER JASON MARCDirector | Buy | 119,000 | $2.93 | $348.7K | Form 4 |
| Dec 6, 2022 | ADLER JASON MARCDirector | Buy | 37,000 | $3.03 | $112.1K | Form 4 |
| Nov 30, 2022 | ADLER JASON MARCDirector | Buy | 6,800 | $3.05 | $20.7K | Form 4 |
| Nov 29, 2022 | ADLER JASON MARCDirector | Buy | 30,200 | $3.04 | $91.8K | Form 4 |
| Nov 28, 2022 | ADLER JASON MARCDirector | Buy | 22,700 | $3.03 | $68.8K | Form 4 |
| Nov 23, 2022 | ADLER JASON MARCDirector | Buy | 3,500 | $3.04 | $10.6K | Form 4 |
All 25 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Michael Gorenstein | 39 | $775.0K | $4.1M66 |
| 2025 | Anna Shlimak | 40 | $356.0K | $1.2M66 |
| 2025 | Jeffrey Jacobson | 40 | $323.1K | $1.1M66 |
| 2025 | Adam Wagner | 43 | $296.8K | $938.4K66 |
| 2025 | Shannon Buggy | 56 | $318.3K | $777.5K66 |
| 2025 | James Holm | $133.3K | $712.3K66 | |
| 2024 | ChairmanPresident and CEO | $775.0K | $4.2M66 | |
| 2024 | Former CFO | $385.0K | $1.5M66 | |
| 2024 | Chief Growth Officer | $312.6K | $1.1M66 | |
| 2024 | CFO | $279.2K | $845.0K66 | |
| 2024 | SVPGlobal Head of People | $300.0K | $770.0K66 | |
| 2023 | ChairmanPresident and CEO | $775.0K | $3.7M66 | |
| 2023 | Chief Growth Officer | $311.3K | $1.4M66 | |
| 2023 | Former CFO | $385.0K | $1.4M66 | |
| 2023 | CFO | $270.0K | $748.9K66 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
2 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Feb 12, 2021 | John A. Yarmuth, House | Buy | $1,001 - $15,000 | −170.4% | Report |
| Nov 5, 2020 | John A. Yarmuth, House | Buy | $1,001 - $15,000 | −170.7% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
SEC filer profile
How Cronos Group Inc is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARCronos Group Inc.2
- CIK0001656472
- Employer ID (EIN)00-00000007
- Filer statusAccelerated filer not an emerging growth company; not a smaller reporting company; not a shell company7
- Incorporated inCanada7
- Fiscal year endsDecember 312
- Industry code (SIC)2833 Medicinal Chemicals & Botanical Products2
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
- Business address4491 Concession Rd 12, Stayner, A6 L0M 1S02
- Mailing address6D - 7398 Yonge St, Pmb 732, Thornhill, A6 L4J 8J22
- Phone(416) 504-00042
- Shares outstanding368,412,864 as of Aug 3, 202614
- Public float$379.9M as of Jun 30, 20257
- AuditorDavidson & Company LLP, Vancouver, BC, Canada PCAOB ID 731; it also attests to the company’s internal control over financial reporting7
- On EDGAR sinceOct 23, 20152
- Filings497 in all: 4 (226), 6-K (75), 8-K (68), 3 (36), 10-Q (20), DEFA14A (8), 10-K (7), DEF 14A (7)2
All 34 form types
SD (7), 4/A (4), 6-K/A (4), 8-K/A (3), SC 13D/A (3), 40-F (2), D (2), F-10/A (2), F-X (2), F-X/A (2), FWP (2), S-8 (2), SC 13D (2), 10-K/A (1), 10-Q/A (1), 3/A (1), 40FR12B (1), 5 (1), CERT (1), F-10 (1), NT 10-K (1), NT 10-Q (1), NT 10-Q/A (1), PRE 14A (1), SC 13G (1), SC 13G/A (1)
- Latest filingsAnnual report (10-K) Feb 26, 2026
Quarterly report (10-Q) Aug 6, 2026
Proxy statement (DEF 14A) Apr 24, 2026
Latest 8-K (8-K) Oct 15, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Shares, no par value | CRON | The Nasdaq Stock Market LLC |
From the cover page of the 10-K filed Feb 26, 2026 (Section 12(b) of the Exchange Act).7
Risk factors and legal proceedings
The risks Cronos Group Inc names in Item 1A of its 10-K filed Feb 26, 2026: 72 risks under these headings, as written.7
- Risks Relating to Our Growth Strategy.
- We have a limited operating history and therefore we are subject to many of the risks common to early-stage enterprises.
- We may not be able to achieve or maintain profitability and may continue to incur losses in the future.
- We may not be able to successfully manage changes in our business or sustain our growth.
- Our use of joint ventures exposes us to risks associated with jointly owned investments.
- There can be no assurance of continued growth in Israel and our performance in Israel depends on, among other things, our ability to continue to import cannabis into Israel and our joint venture partners.
- Our acquisition strategy may not be successful, and we have in the past, and may in the future, need to write down goodwill and intangible assets recognized upon acquisition.
- Consummation of our planned acquisition of CanAdelaar is subject to closing conditions and regulatory approvals, and the transaction may be delayed, incur additional costs, or fail to close. If completed, we may face integration challenges and future unforeseen obligations based on CanAdelaar’s operating performance following closing.
- We have had multiple restatements and material weaknesses in our internal control over financial reporting in the past. We have experienced significant turnover, both voluntary and involuntary, in our accounting and financial reporting functions, as well as in our internal audit function. If we are unable to create and maintain an appropriate control environment, our business, results of operations, financial condition, cash flows and reputation will be adversely affected.
- We are subject to disabilities as a result of our settlement with the SEC that may expose us to increased future litigation and adversely affect our ability to raise capital.
- There can be no assurance that our current and future strategic alliances or expansions of existing relationships will have a beneficial impact on our business, financial condition and results of operations.
- Wholesale price volatility could have a material adverse effect on our business.
The other 60 risks
- We may be unable to obtain adequate supplies of raw materials in a timely manner and at commercially reasonable prices.
- Our option to purchase a significant portion of Cronos GrowCo’s production could strain Cronos GrowCo’s ability to develop, maintain and grow profitable relationships with third-party customers.
- Termination or non-renewal of the Cronos GrowCo Supply Agreement could have a material negative impact on our ability to obtain cannabis biomass at commercially viable prices.
- We may not successfully execute or sustain our production capacity strategy.
- We may not be able to successfully procure rare cannabinoids at commercially viable prices or in the quantities that we require.
- There can be no assurance that recent operational and strategic initiatives will have a beneficial impact on our business, financial condition and results of operations. The timing, costs and benefits thereof cannot be guaranteed.
- The industries and markets in which we operate are relatively new and may not continue to exist or grow as anticipated, and we may ultimately be unable to succeed in these industries and markets.
- We may not be able to supply the purchasers in various provinces and territories of Canada with our products in the quantities or prices anticipated, or at all, due to the discretion such purchasers have over purchasing, pricing, and product listings.
- The adult-use cannabis market in Canada has in the past been and may in the future become oversupplied.
- We may be unsuccessful in competing in the legal adult-use cannabis market in Canada.
- We are subject to liability arising from any fraudulent or illegal activity by our employees, contractors, manufacturers and consultants.
- Some jurisdictions may never develop markets for cannabis.
- Our U.S. strategy in part depends on the success of the PharmaCann Investment and there is no guarantee that we will exercise the PharmaCann Option in the near term, or at all, and, even if exercised, that the PharmaCann Investment will achieve the expected benefits of the PharmaCann Investment.
- We rely largely on our own market research to forecast sales and market demand and market prices may differ from our forecasts.
- We could have difficulty integrating the operations of businesses that we have acquired and will acquire.
- We have been, and may in the future be, required to write down intangible assets, including goodwill, due to impairment, which could have a material adverse effect on our results of operations or financial position.
- Risks Relating to Operations in Israel
- Conditions in Israel could materially and adversely affect our business, financial condition, and results of operations.
- Our operations may be disrupted by the obligations of personnel to perform military service.
- The imposition of an anti-dumping duty on our imports into Israel could have a material adverse effect on our business, financial condition and results of operations.
- Risks Relating to Our Products
- There is limited long-term data with respect to the efficacy and side effects of cannabis and cannabinoids, and future clinical research studies on the effects of cannabis and cannabinoids may lead to conclusions that dispute or conflict with our understanding and belief regarding their benefits, viability, safety, efficacy, dosing and social acceptance.
- Clinical trials of cannabis-based medical products and treatments have a limited history, and any trials may not result in commercially viable products and treatments.
- The controversy surrounding vaporizers and vaporizer products may materially and adversely affect the market for vaporizer products and expose us to litigation and additional regulation.
- Future research may lead to findings that vaporizers, electronic cigarettes and related products are not safe for their intended use.
- We, or the cannabis industry more generally, may receive unfavorable publicity or become subject to negative consumer perception.
- We may be subject to litigation in the ordinary course of our marketing, distribution and sale of our products.
- We may be subject to product liability claims.
- Our products have in the past and may in the future be subject to recalls.
- We rely on third-party testing and analytical methods which are validated but have not yet been standardized.
- We may not be able to successfully develop new products or find a market for their sale.
- The Canadian excise duty framework may adversely affect our profitability.
- Our business may be impacted by conditions in the global economy and financial markets, including changes in inflation, interest rates, trade policy and overall economic conditions.
- Risks Relating to Production and Distribution of Products
- Our production facilities, and those of our strategic joint ventures, are integral to our operations, and any adverse changes or developments affecting such facilities may impact our business, financial condition and results of operations.
- We have in the past and may in the future experience unauthorized access to our information technology systems or other cybersecurity incidents, which could disrupt our operations and have a material adverse effect on our business.
- Any actual or perceived failure by us to comply with laws, regulations or any other obligations relating to privacy, data protection or the protection or transfer of personal data, could adversely affect our business.
- Our cannabis cultivation operations are subject to risks inherent in an agricultural business.
- The inability of our suppliers to meet their financial or contractual obligations to us may result in disruption to our supply chain and could result in financial losses.
- We rely on third-party distributors and manufacturers to distribute and manufacture certain of our products, and those distributors and manufacturers may not perform their obligations.
- Risks Relating to Intellectual Property
- We are subject to risks related to the protection and enforcement of our intellectual property rights, and we may be unable to protect or enforce our intellectual property rights.
- We may be unable to protect our inventions, trade secrets, and other intellectual property from discovery or unauthorized use or disclosure.
- Our intellectual property rights may be invalid or unenforceable under applicable laws, and we may be unable to have issued or registered, and unable to enforce, our intellectual property rights.
- We may be subject to allegations that we are in violation of third-party intellectual property rights, and we may be found to infringe third-party intellectual property rights, possibly without the ability to obtain licenses necessary to use such third-party intellectual property rights.
- Our germplasm relies heavily on intellectual property, and we may be unable to protect, register or enforce our intellectual property rights in germplasm and may infringe third-party intellectual property rights with respect to germplasm, possibly without the ability to obtain licenses necessary to use such third-party intellectual property rights.
- We receive licenses to use some third-party intellectual property rights and germplasm; the failure of the owner of such intellectual property or germplasm to properly maintain or enforce the intellectual property underlying such licenses or germplasm, as the case may be, or our inability to obtain or maintain such licenses, could have a material adverse effect on our business, financial condition and performance.
- The technologies, processes and formulations we use may face competition or become obsolete.
- Risks Relating to Entry into New Markets
- Entering into new jurisdictions is inherently risky, may not be successful and could be costly.
- Our expansion into the Netherlands exposes us to unique regulatory and commercial risks associated with the Dutch cannabis market.
- Controlled substance and other legislation and treaties may restrict or limit our ability to research, manufacture and develop a commercial market for our products outside of the jurisdictions in which we currently operate, and our expansion into such jurisdictions is subject to risks.
- Investments and joint ventures outside of Canada are subject to the risks normally associated with any conduct of business in foreign countries, including varying degrees of political, legal, regulatory and economic risk.
- Risks Relating to Regulation and Compliance
- We operate in highly regulated sectors where the regulatory environment is rapidly developing, and we may not always succeed in complying fully with applicable regulatory requirements in all jurisdictions where we carry on business.
- We and our joint ventures and strategic investments are reliant on required licenses, authorizations, approvals and permits for our ability to grow, process, store and sell cannabis and cannabinoids which are subject to ongoing compliance, reporting and renewal requirements, and we may also be required to obtain additional licenses, authorizations, approvals and permits in connection with our business.
- Changes in the laws, regulations and guidelines governing cannabis may adversely impact our business.
- We are subject to certain restrictions of the TSX and Nasdaq, which may constrain our ability to expand our business internationally.
- We are constrained by law in our ability to market and advertise our products.
- Any rescheduling of U.S. Schedule I cannabis to Schedule III would have an uncertain impact on our business.
- The legal and regulatory framework governing U.S. hemp and hemp-derived products is complex, evolving, and subject to significant uncertainty.
- Risks Relating to Competition
- The markets in which we operate are increasingly competitive, and we may compete for market share with other companies, both domestically and internationally, that may have longer operating histories and more financial resources, manufacturing, distribution, and marketing experience than us.
- We face competition from the illegal cannabis market.
- Regulatory non-compliance by licensed cannabis competitors may have an adverse effect on our business, results of operations and financial condition.
- We have been and may in the future be required to write down inventory due to downward pressure on market prices, which could have a material adverse effect on our results of operations or financial position.
- We may be unable to attract or retain skilled labor and personnel with experience in the cannabis sector and may be unable to attract, develop and retain additional employees required for our operations and future developments.
- Risks Relating to the Altria Investment
Legal proceedings
The Company is subject to various legal proceedings in the ordinary course of its business and in connection with its marketing, distribution and sale of its products. Many of these legal proceedings are in the early stages of litigation and seek damages that are unspecified or not quantified. Although the outcome of these matters cannot be predicted with certainty, the Company does not believe these legal proceedings, individually or in the aggregate, will have a material adverse effect on its consolidated financial condition but could be material to its results of operations for any particular reporting period depending, in part, on its results for that period. See Part II, Note 12(b) “Contingencies,” to the consolidated financial statements under Item 8 of this Annual Report for a description of legal proceedings.
The opening of Item 3, Legal Proceedings.7
Links
- Websitethecronosgroup.com1
- LinkedInwww.linkedin.com/company/cronos-group1
- WikidataQ75256038
- SEC EDGARCIK 1656472
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataCronos Group Inc on Wikidata
- 2
- 3
- 4Company websiteCronos Group Inc logo
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16SEC EDGARMichael Gorenstein, Chair
- 17SEC EDGARJames Holm, Chief financial officer
- 18
- 19
- 20SEC EDGARJared Matthew Kenost, Officer
- 21
- 22
- 23
- 24SEC EDGARJohn Griese, Officer
- 25
- 26
- 27SEC EDGARArye Weigensberg, Officer
- 28SEC EDGARCarlos S. Cortez, VP, Controller
- 29SEC EDGARAnna Shlimak, SVP, Corporate Affairs
- 30SEC EDGARSummer Frein, General Manager, USA
- 31SEC EDGARKurt Schmidt, Officer
- 32
- 33SEC EDGARJeffrey David Jacobson, Officer
- 34SEC EDGARMichael Gorenstein, Officer
- 35
- 36SEC EDGARRobert Steven Rosenheck, Officer
- 37SEC EDGARXiu Ming Shum, Officer
- 38
- 39SEC EDGARDominik Meier, Board member
- 40SEC EDGARElizabeth Seegar, Board member
- 41
- 42SEC EDGARHeather A. Newman, Board member
- 43
- 44SEC EDGARBruce Allen Gates, Board member
- 45SEC EDGARJames Daniel Rudyk, Board member
- 46SEC EDGARJason Marc Adler, Board member
- 47SEC EDGARJody L. Begley, Board member
- 48SEC EDGARMurray R. Garnick, Board member
- 49
- 50SEC EDGAREntered a material agreement
- 51SEC EDGARShareholder vote
- 52SEC EDGARResults of operations
- 53SEC EDGARShareholder vote
- 54
- 55SEC EDGARResults of operations
- 56
- 57SEC EDGARResults of operations
- 58SEC EDGARExecutive or director change
- 59
- 60SEC EDGARShareholder vote
- 61NasdaqNasdaq calendar
- 62
- 63
- 64
- 65SEC EDGARAltria SC 13D/A on Cronos Group Inc
- 66